Most patients are microdosing due to the following reasons: Mitigating side effects Semaglutide is associated with various side effects like nausea, vomiting, abdominal pain, diarrhea, and constipation
It also protects your cells from oxidative stress caused by pollution and lifestyle factors
2012), whether these biomarkers went through analytical biomarker verification and whether these biomarkers have been observed in clinical studies (Bhattacharyya et al
Current pharmacotherapy for obesity
Providers may recommend switching to selective COX-2 inhibitors (celecoxib), which carry lower renal risk than non-selective NSAIDs like ibuprofen or naproxen
2023 Phase 2 obesity trial and produced approximately 24% mean weight loss at 48 weeks, but with a clearly higher gastrointestinal adverse-event burden than 8 mg [5][2]